Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | JAK3 | P52333 | 1/20 | 0.48 |
| ▸ | CSNK2A1 | P68400 | 6/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.39 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 5/20 | 0.39 |
| ▸ | AXL | P30530 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3448430 | 0.89 | LCK (0.45) | LCKJAK3CSNK2A1EGFRAXL | |
| SCHEMBL3447604 | 0.88 | CSNK2A1 (0.43) | CSNK2A1EGFRXDHSLC22A12CSNK2A2 | |
| SCHEMBL3449234 | 0.86 | XDH (0.43) | LCKJAK3CSNK2A1EGFRXDH | |
| SCHEMBL3447674 | 0.86 | JAK3 (0.43) | LCKJAK3CSNK2A1EGFRXDH | |
| SCHEMBL3449527 | 0.85 | CSNK2A1 (0.43) | CSNK2A1EGFRXDHSLC22A12CSNK2A2 | |
| SCHEMBL3448886 | 0.85 | KIT (0.43) | LCKJAK3CSNK2A1EGFRXDH | |
| SCHEMBL3447741 | 0.85 | JAK3 (0.44) | LCKJAK3CSNK2A1EGFRXDH | |
| SCHEMBL3451174 | 0.85 | JAK3 (0.44) | LCKJAK3CSNK2A1EGFRXDH | |
| SCHEMBL3449427 | 0.83 | AXL (0.50) | CSNK2A1EGFRXDHSLC22A12AXL | |
| SCHEMBL3450574 | 0.83 | F11 (0.44) | CSNK2A1EGFRXDHSLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | LCK 1761/4885JAK3 2419/4885CSNK2A1 1858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.